Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Buy
58
UTHR Quote, Financials, Valuation and Earnings
Last price:
$314.18
Seasonality move
:
3.89%
Day range:
$304.55 - $324.22
52-week range:
$221.53 - $417.82
Dividend yield:
0%
P/E ratio:
13.13x
P/S ratio:
5.45x
P/B ratio:
2.25x
Volume:
400.6K
Avg. volume:
555.4K
1-year change:
36.97%
Market cap:
$14.5B
Revenue:
$2.9B
EPS (TTM):
$24.60
Analysts' Opinion
-
Consensus RatingUnited Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $397.54, United Therapeutics has an estimated upside of 23.82% from its current price of $322.94.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $293.00 representing 9.27% downside risk from its current price of $322.94.
Fair Value
-
According to the consensus of 12 analysts, United Therapeutics has 23.82% upside to fair value with a price target of $397.54 per share.
UTHR vs. S&P 500
-
Over the past 5 trading days, United Therapeutics has overperformed the S&P 500 by 0.24% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
United Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
United Therapeutics has grown year-over-year revenues for 17 quarters straight. In the most recent quarter United Therapeutics reported revenues of $735.9M.
Earnings Growth
-
United Therapeutics has grown year-over-year earnings for 7 quarters straight. In the most recent quarter United Therapeutics reported earnings per share of $6.19.
Enterprise value:
11.5B
EV / Invested capital:
1.71x
Price / LTM sales:
5.45x
EV / EBIT:
7.29x
EV / Revenue:
4.01x
PEG ratio (5yr expected):
0.55x
EV / Free cash flow:
10.68x
Price / Operating cash flow:
14.50x
Enterprise value / EBITDA:
6.97x
Gross Profit (TTM):
$2.6B
Return On Assets:
17.14%
Net Income Margin (TTM):
41.53%
Return On Equity:
20.21%
Return On Invested Capital:
18.64%
Operating Margin:
49.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.9B | $2.3B | $2.9B | $614.7M | $735.9M | |
| Gross Profit | $1.8B | $2.1B | $2.6B | $543.7M | $660M | |
| Operating Income | $979.7M | $1.2B | $1.4B | $260.1M | $363.7M | |
| EBITDA | $1B | $1.4B | $1.7B | $324.2M | $424.1M | |
| Diluted EPS | $15.02 | $19.84 | $24.60 | $4.36 | $6.19 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $2.3B | $3.4B | $3.6B | $3.9B | |
| Total Assets | $4.6B | $5.2B | $6B | $7.2B | $7.4B | |
| Current Liabilities | $323.3M | $305.4M | $343.2M | $804.4M | $738.1M | |
| Total Liabilities | $1.2B | $1.2B | $1.2B | $1.2B | $920M | |
| Total Equity | $3.4B | $4B | $4.8B | $6B | $6.4B | |
| Total Debt | $800M | $800M | $800M | $700M | $300M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $802.5M | $978M | $1.3B | $150.7M | $341.2M | |
| Cash From Investing | -$811.5M | -$719.6M | $417.2M | $42.1M | -$123.2M | |
| Cash From Financing | $75.4M | -$11.9M | -$1.3B | -$92.8M | -$74.7M | |
| Free Cash Flow | $663.7M | $747.6M | $1.1B | $72M | $254.5M | |
UTHR
Sector
Market Cap
$14.5B
$37.4M
Price % of 52-Week High
77.29%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
7.03%
-0.75%
1-Year Price Total Return
36.97%
-38.36%
Beta (5-Year)
0.638
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$310.15
200-day SMA
Sell
Level
$343.81
Bollinger Bands (100)
Sell
Level
337.96 - 382
Chaikin Money Flow
Buy
Level
92.8M
20-day SMA
Sell
Level
$332.11
Relative Strength Index (RSI14)
Sell
Level
45.53
ADX Line
Sell
Level
31.76
Williams %R
Neutral
Level
-48.2356
50-day SMA
Sell
Level
$349.30
MACD (12, 26)
Sell
Level
-13.16
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
99M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.2999)
Buy
CA Score
(Annual)
Level (2.3029)
Sell
Beneish M-Score
(Annual)
Level (-2.0594)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-6.6902)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Stock Forecast FAQ
In the current month, UTHR has received 7 Buy ratings 5 Hold ratings, and 0 Sell ratings. The UTHR average analyst price target in the past 3 months is $397.54.
-
Where Will United Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that United Therapeutics share price will rise to $397.54 per share over the next 12 months.
-
What Do Analysts Say About United Therapeutics?
Analysts are divided on their view about United Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that United Therapeutics is a Sell and believe this share price will drop from its current level to $293.00.
-
What Is United Therapeutics's Price Target?
The price target for United Therapeutics over the next 1-year time period is forecast to be $397.54 according to 12 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is UTHR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for United Therapeutics is a Buy. 7 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of UTHR?
You can purchase shares of United Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase United Therapeutics shares.
-
What Is The United Therapeutics Share Price Today?
United Therapeutics was last trading at $314.18 per share. This represents the most recent stock quote for United Therapeutics. Yesterday, United Therapeutics closed at $322.94 per share.
-
How To Buy United Therapeutics Stock Online?
In order to purchase United Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
